BOLD
Boundless Bio, Inc.
2.46
+0.01 (+0.41%)
52w low 0.9610
3.16 high
68.0% of range
Open
2.46
High
2.46
Low
2.39
Prev Close
2.45
Volume
10.83K
Avg Vol 3M
140.06K
Market Cap
57.04M
Currency
USD
6 Month Trend
—
C--
Chg--
Gap--
Vol--
×avg--
σ--
SMA20--
SMA50--
SMA200--
RSI--
SPY--
DD--
Bench--
Sig--
Hist--
pinned · Esc to release
hover · click to pin · ← → step · drag to zoom · shift-drag to measure
—Context
- Move across the chart.
Company
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| Employees | 28 |
| Web | site ↗ |
Performance
1D
+0.41%
5D
+2.50%
1M
-3.53%
3M
-11.51%
6M
+59.74%
YTD
+105.00%
1Y
+95.24%
2Y
-31.28%
3Y
--
5Y
--
MAX
-82.74%
Valuation
| P/E Trailing | -- |
| P/E Forward | -2.50x |
| Price / Book | 0.83x |
| Price / Sales | -- |
| EV / EBITDA | 0.26x |
| EPS Trailing | -2.85 |
| Dividend Yield | 0.00% |
| Beta | 0.46 |
Profitability
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -67.86% |
| Return on Assets | -32.77% |
| Revenue Growth | -- |
| Debt / Equity | -- |
| Current Ratio | 9.48x |
Business
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.